Temporal trends of nonalcoholic fatty liver disease-related hepatocellular carcinoma in the veteran affairs population

Clinical Gastroenterology and Hepatology

Volumn 13, Issue 3, 2015, Pages 594-601.e1

  Mittal, Sahil ^a,c   Sada, Yvonne H ^a   El Serag, Hashem B ^a,b,c   Kanwal, Fasiha ^a,b,c   Duan, Zhigang ^a   Temple, Sarah ^a   May, Sarah B ^a   Kramer, Jennifer R ^a   Richardson, Peter A ^a   Davila, Jessica A ^a  

^a Center of Innovation Effectiveness and Quality Sections of Health Services Research Section of Gastroenterology and Hepatology   (United States)

^b MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Incidence; Liver cancer; NASH; Time

Indexed keywords

ALPHA FETOPROTEIN;

ABLATION THERAPY; AGED; ALCOHOL ABUSE; ALCOHOL LIVER DISEASE; ALPHA 1 ANTITRYPSIN DEFICIENCY; ARTICLE; AUTOIMMUNE HEPATITIS; CANCER MORTALITY; CANCER SURGERY; CANCER SURVIVAL; COMORBIDITY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; FEMALE; HEMOCHROMATOSIS; HEPATITIS B; HEPATITIS C; HUMAN; HYPERTENSION; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER HISTOLOGY; LIVER RESECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; OUTCOME ASSESSMENT; PREVALENCE; RISK FACTOR; VETERAN; CARCINOMA, HEPATOCELLULAR; COHORT ANALYSIS; COMPLICATION; LIVER NEOPLASMS; MIDDLE AGED; UNITED STATES;

AGED; CARCINOMA, HEPATOCELLULAR; COHORT STUDIES; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PREVALENCE; UNITED STATES; VETERANS;

EID: 84925359459     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2014.08.013     Document Type: Article

References (40)

1. El-Serag H.B., Davila J.A., Petersen N.J., et al. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med 2003, 139:817-823.
2. McGlynn K.A., Tarone R.E., El-Serag H.B. Acomparison of trends in the incidence of hepatocellular carcinoma and intrahepatic cholangiocarcinoma in the United States. Cancer Epidemiol Biomarkers Prev 2006, 15:1198-1203.
3. Davila J.A., Morgan R.O., Shaib Y., et al. Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: a population-based study. Gastroenterology 2004, 127:1372-1380.
4. Adams L.A., Lindor K.D. Nonalcoholic fatty liver disease. Ann Epidemiol 2007, 17:863-869.
5. Williams C.D., Stengel J., Asike M.I., et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 2011, 140:124-131.
6. Vernon G., Baranova A., Younossi Z.M. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011, 34:274-285.
7. Bugianesi E., Leone N., Vanni E., et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002, 123:134-140.
8. Caldwell S.H., Oelsner D.H., Iezzoni J.C., et al. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 1999, 29:664-669.
9. Afzali A., Berry K., Ioannou G.N. Excellent posttransplant survival for patients with nonalcoholic steatohepatitis in the United States. Liver Transpl 2012, 18:29-37.
10. White D.L., Kanwal F., El-Serag H.B. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin Gastroenterol Hepatol 2012, 10:1342-1359.
11. Marrero J.A., Fontana R.J., Su G.L., et al. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology 2002, 36:1349-1354.
12. Guzman G., Brunt E.M., Petrovic L.M., et al. Does nonalcoholic fatty liver disease predispose patients to hepatocellular carcinoma in the absence of cirrhosis?. Arch Pathol Lab Med 2008, 132:1761-1766.
13. Reddy S.K., Steel J.L., Chen H.W., et al. Outcomes of curative treatment for hepatocellular cancer in nonalcoholic steatohepatitis versus hepatitis C and alcoholic liver disease. Hepatology 2012, 55:1809-1819.
14. VA Information Resource Center. Available at: . Accessed June 20, 2013. http://www.virec.reserach.va.gov/VSF/Overview.htm.
15. Davila J.A., Weston A., Smalley W., et al. Utilization of screening for hepatocellular carcinoma in the United States. JClin Gastroenterol 2007, 41:777-782.
16. Bruix J., Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011, 53:1020-1022.
17. Llovet J.M., Ducreux M., Lencioni R., et al. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. JHepatol 2012, 56:908-943.
18. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001, 285:2486-2497.
19. Ascha M.S., Hanouneh I.A., Lopez R., et al. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 2010, 51:1972-1978.
20. Deyo R.A., Cherkin D.C., Ciol M.A. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. JClin Epidemiol 1992, 45:613-619.
21. El-Serag H.B., Mason A.C. Risk factors for the rising rates of primary liver cancer in the United States. Arch Intern Med 2000, 160:3227-3230.
22. Thomas D.L. Global control of hepatitis C: where challenge meets opportunity. Nat Med 2013, 19:850-858.
23. Yang J.D., Harmsen W.S., Slettedahl S.W., et al. Factors that affect risk for hepatocellular carcinoma and effects of surveillance. Clin Gastroenterol Hepatol 2011, 9:617-623.
24. Giannini E.G., Marabotto E., Savarino V., et al. Hepatocellular carcinoma in patients with cryptogenic cirrhosis. Clin Gastroenterol Hepatol 2009, 7:580-585.
25. Browning J.D., Szczepaniak L.S., Dobbins R., et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004, 40:1387-1395.
26. Giday S.A., Ashiny Z., Naab T., et al. Frequency of nonalcoholic fatty liver disease and degree of hepatic steatosis in African-American patients. JNatl Med Assoc 2006, 98:1613-1615.
27. Solga S.F., Clark J.M., Alkhuraishi A.R., et al. Race and comorbid factors predict nonalcoholic fatty liver disease histopathology in severely obese patients. Surg Obes Relat Dis 2005, 1:6-11.
28. Browning J.D., Kumar K.S., Saboorian M.H., et al. Ethnic differences in the prevalence of cryptogenic cirrhosis. Am J Gastroenterol 2004, 99:292-298.
29. Calle E.E., Rodriguez C., Walker-Thurmond K., et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. NEngl J Med 2003, 348:1625-1638.
30. Moller H., Mellemgaard A., Lindvig K., et al. Obesity and cancer risk: a Danish record-linkage study. Eur J Cancer 1994, 30A:344-350.
31. Oh S.W., Yoon Y.S., Shin S.A. Effects of excess weight on cancer incidences depending on cancer sites and histologic findings among men: Korea National Health Insurance Corporation Study. JClin Oncol 2005, 23:4742-4754.
32. Adami H.O., Chow W.H., Nyren O., et al. Excess risk of primary liver cancer in patients with diabetes mellitus. JNatl Cancer Inst 1996, 88:1472-1477.
33. El-Serag H.B., Richardson P.A., Everhart J.E. The role of diabetes in hepatocellular carcinoma: a case-control study among United States Veterans. Am J Gastroenterol 2001, 96:2462-2467.
34. El-Serag H.B., Tran T., Everhart J.E. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 2004, 126:460-468.
35. Farrell G. Insulin resistance, obesity, and liver cancer. Clin Gastroenterol Hepatol 2014, 12:117-119.
36. Mair R.D., Valenzuela A., Ha N.B., et al. Incidence of hepatocellular carcinoma among US patients with cirrhosis of viral or nonviral etiologies. Clin Gastroenterol Hepatol 2012, 10:1412-1417.
37. Torres D.M., Williams C.D., Harrison S.A. Features, diagnosis, and treatment of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2012, 10:837-858.
38. Anew prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology 1998, 28:751-755.
39. Regimbeau J.M., Colombat M., Mognol P., et al. Obesity and diabetes as a risk factor for hepatocellular carcinoma. Liver Transpl 2004, 10:S69-S73.
40. Paradis V., Zalinski S., Chelbi E., et al. Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis. Hepatology 2009, 49:851-859.